Published in BMC Cancer on August 29, 2010
The clinical approach toward giant cell tumor of bone. Oncologist (2014) 1.46
Giant cell tumors of the axial skeleton. Sarcoma (2012) 1.29
Primary hyperparathyroidism diagnosed after surgical ablation of a costal mass mistaken for giant-cell bone tumor: a case report. J Med Case Rep (2011) 1.22
Osteoclasts: more than 'bone eaters'. Trends Mol Med (2014) 1.17
Pulmonary metastasis of giant cell tumor of bones. World J Surg Oncol (2014) 1.06
A short-term in vivo model for giant cell tumor of bone. BMC Cancer (2011) 0.92
Intralesional excision versus wide resection for giant cell tumor involving the acetabulum: which is better? Clin Orthop Relat Res (2011) 0.87
Giant cell tumour of bone: new treatments in development. Clin Transl Oncol (2015) 0.87
Treatment and outcome of primary aggressive giant cell tumor in the spine. Eur Spine J (2015) 0.84
Giant-cell tumor of bone, anti-RANKL therapy. Bonekey Rep (2012) 0.84
Giant-cell tumor of bone: treatment options and role of denosumab. Biologics (2015) 0.81
Therapeutic radiotherapy for giant cell tumor of the spine: a systemic review. Eur Spine J (2015) 0.80
Aggressive aneurysmal bone cyst in association with polyostotic fibrous dysplasia: A case report. Int J Surg Case Rep (2015) 0.76
Successful treatment with denosumab in a patient with sacral giant cell tumor of bone refractory to combination therapy with arterial embolization and zoledronic acid: A case report. Mol Clin Oncol (2017) 0.75
Clinical Outcome of Treatment for Patients with Giant Cell Tumor in Spine. J Korean Neurosurg Soc (2015) 0.75
A case of thoracic giant cell tumor of bone and discussion of radiological features and current management practices. Radiol Case Rep (2016) 0.75
Differential Expression of ADAM23, CDKN2A (P16), MMP14 and VIM Associated with Giant Cell Tumor of Bone. J Cancer (2015) 0.75
Treatment options and prognosis for repeatedly recurrent giant cell tumor of the spine. Eur Spine J (2016) 0.75
Diagnosing giant cell tumor of the bone using positron emission tomography/computed tomography: A retrospective study of 20 patients from a single center. Oncol Lett (2017) 0.75
Giant cell tumor of the fifth lumbar vertebra with a three-year follow-up: case report and review of the literature. Eur J Orthop Surg Traumatol (2012) 0.75
Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). Cancer Chemother Pharmacol (2017) 0.75
Giant cell tumor of bone revisited. SICOT J (2017) 0.75
Giant-cell tumor of bone. J Bone Joint Surg Am (1987) 7.92
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol (2010) 6.47
Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 3.57
Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am (1999) 3.45
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res (1995) 3.23
Giant cell tumor of bone. Orthop Clin North Am (2006) 3.07
Giant cell tumor of bone. Am J Clin Oncol (2006) 2.15
Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol (1990) 1.94
Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res (2007) 1.94
Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone (2007) 1.77
Cellular and hormonal mechanisms associated with malignant bone resorption. Lab Invest (1994) 1.53
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res (1997) 1.42
Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clin Orthop Relat Res (2004) 1.41
Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol (1998) 1.39
Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res (2001) 1.26
Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int (2004) 1.24
Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol (2005) 1.15
Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone (1996) 1.07
Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain. J Pain Symptom Manage (2009) 1.06
Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol (2001) 0.95
Review of cellular mechanisms of tumor osteolysis. Clin Orthop Relat Res (2000) 0.93
Bisphosphonate inhibition of bone resorption induced by particulate biomaterial-associated macrophages. Acta Orthop Scand (1996) 0.91
Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration. Ultrastruct Pathol (2003) 0.91
Osteonecrosis of the jaw. Skeletal Radiol (2008) 0.87
Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature. J Med Assoc Thai (2008) 0.84
Analgesia for patients with advanced disease: 2. Postgrad Med J (2004) 0.78
Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone. Sarcoma (2003) 0.78
UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf) (2011) 3.28
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer (2006) 3.11
Mortality in the Islamic Republic of Iran, 1964-2004. Bull World Health Organ (2007) 2.93
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol (2012) 2.67
Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol (2008) 2.63
Health for all beyond 2000: the demise of the Alma-Ata Declaration and primary health care in developing countries. Med J Aust (2003) 2.55
Fructose consumption and consequences for glycation, plasma triacylglycerol, and body weight: meta-analyses and meta-regression models of intervention studies. Am J Clin Nutr (2008) 2.30
Chordoma of the mobile spine: fifty years of experience. Spine (Phila Pa 1976) (2006) 2.23
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol (2005) 2.17
Glycemic response and health--a systematic review and meta-analysis: relations between dietary glycemic properties and health outcomes. Am J Clin Nutr (2008) 2.14
Endoprosthetic reconstruction in 250 patients with sarcoma. Clin Orthop Relat Res (2006) 2.13
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res (2005) 2.09
The effects of involuntary job loss on suicide and suicide attempts among young adults: evidence from a matched case-control study. Aust N Z J Psychiatry (2014) 1.98
Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol (2005) 1.94
Rapid assessment of exposure to chlorine released from a train derailment and resulting health impact. Public Health Rep (2007) 1.82
Association between Agent Orange and birth defects: systematic review and meta-analysis. Int J Epidemiol (2006) 1.82
Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol (2003) 1.79
Attributable risk of psychiatric and socio-economic factors for suicide from individual-level, population-based studies: a systematic review. Soc Sci Med (2010) 1.73
The role of under-employment and unemployment in recent birth cohort effects in Australian suicide. Soc Sci Med (2013) 1.67
Lack of toxicological side-effects in silver-coated megaprostheses in humans. Biomaterials (2007) 1.66
Impact of misclassification on measures of cardiovascular disease mortality in the Islamic Republic of Iran: a cross-sectional study. Bull World Health Organ (2008) 1.66
Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol (2012) 1.63
Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer (2005) 1.62
Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials (2003) 1.61
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics (2009) 1.57
Is there a dose-response relation of dietary glycemic load to risk of type 2 diabetes? Meta-analysis of prospective cohort studies. Am J Clin Nutr (2013) 1.55
Did it fall or was it pushed? The contribution of trends in established risk factors to the decline in premature coronary heart disease mortality in New Zealand. Aust N Z J Public Health (2008) 1.52
NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res (2010) 1.52
Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer (2014) 1.51
The correlation of wear with histological features after failed hip resurfacing arthroplasty. J Bone Joint Surg Am (2013) 1.45
In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene (2005) 1.44
The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol (2010) 1.43
Loci for regulation of bone mineral density in men and women identified by genome wide linkage scan: the FAMOS study. Hum Mol Genet (2005) 1.42
Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther (2010) 1.41
Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Arch (2009) 1.39
New information on the mechanism of forcible ascospore discharge from Ascobolus immersus. Fungal Genet Biol (2004) 1.37
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet (2012) 1.37
Clinical outcome of central conventional chondrosarcoma. J Surg Oncol (2012) 1.37
Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol (2007) 1.36
Who has regular mammograms? Effects of knowledge, beliefs, socioeconomic status, and health-related factors. Prev Med (2005) 1.36
The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol (2002) 1.35
miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol (2012) 1.34
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist (2008) 1.31
Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol (2009) 1.28
Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer (2009) 1.26
Is age at diagnosis an independent prognostic factor for survival following breast cancer? ANZ J Surg (2005) 1.25
Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma. Clin Cancer Res (2007) 1.25
Rural Indian tribal communities: an emerging high-risk group for HIV/AIDS. BMC Int Health Hum Rights (2005) 1.24
The decline in coronary heart disease mortality is slowing in young adults (Australia 1976-2006): a time trend analysis. Int J Cardiol (2011) 1.23
Mortality trends in Fiji. Aust N Z J Public Health (2011) 1.23
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
Mortality trends and the epidemiological transition in Nauru. Asia Pac J Public Health (2011) 1.21
Socio-economic mortality differentials in Sydney over a quarter of a century, 1970-94. Aust N Z J Public Health (2002) 1.21
Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs (2010) 1.21
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer (2009) 1.20
miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol (2012) 1.18
Population-based mammography screening and breast cancer incidence in New South Wales, Australia. Cancer Causes Control (2006) 1.17
Cancer detection and mammogram volume of radiologists in a population-based screening programme. Breast (2005) 1.17
Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of "protective" and "risk" factors. J Bone Joint Surg Am (2011) 1.17
Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol (2005) 1.15
Intrathecal morphine for postoperative analgesia: a randomized, controlled, dose-ranging study after hip and knee arthroplasty. Anesth Analg (2003) 1.15
Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res (2009) 1.15
Advantages of normothermic perfusion over cold storage in liver preservation. Transplantation (2002) 1.14
Mortality and cause-of-death reporting and analysis systems in seven Pacific Island countries. BMC Public Health (2012) 1.13
Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene (2004) 1.12
Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol (2008) 1.12
Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer (2005) 1.10
CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest (2010) 1.10
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res (2013) 1.09
Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther (2002) 1.09
Preservation of porcine non-heart-beating donor livers by sequential cold storage and warm perfusion. Transplantation (2004) 1.09
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer (2002) 1.09
Cerebrovascular disease in 48 countries: secular trends in mortality 1950-2005. J Neurol Neurosurg Psychiatry (2011) 1.08
Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res (2007) 1.07
Causes of death in Tonga: quality of certification and implications for statistics. Popul Health Metr (2012) 1.07
Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol (2009) 1.07
Primary high-grade osteosarcoma: comparison between preadolescent and older patients. J Pediatr Hematol Oncol (2005) 1.06
Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer (2009) 1.04
Prognostic value of CCN3 in osteosarcoma. Clin Cancer Res (2008) 1.04
Molecular diagnosis in Ewing family tumors: the Rizzoli experience--222 consecutive cases in four years. J Mol Diagn (2011) 1.03
Morphologic characterization of osteosarcoma growth on the chick chorioallantoic membrane. BMC Res Notes (2010) 1.03
Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep (2003) 1.02
Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res (2008) 1.02
Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer (2011) 1.01
Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer (2004) 1.01
Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer (2005) 1.01
Cerebrotendinous xanthomatosis presenting with bilateral Achilles tendon xanthomata. Skeletal Radiol (2006) 1.00
Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. J Pediatr Hematol Oncol (2005) 1.00
CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell (2006) 1.00
Switching to fast growth: the insulin-like growth factor (IGF) system in skeletal muscle of Atlantic salmon. J Exp Biol (2008) 0.99
Paternal exposure to Agent Orange and spina bifida: a meta-analysis. Eur J Epidemiol (2009) 0.99
Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years. Acta Orthop Scand (2004) 0.99
Distress and quality of life in primary high-grade brain tumor patients. Support Care Cancer (2009) 0.99
Adjuvant chemotherapy for soft tissue sarcoma. Curr Opin Oncol (2005) 0.98
Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. Eur J Cancer (2011) 0.98
Further increases in rural suicide in young Australian adults: secular trends, 1979-2003. Soc Sci Med (2007) 0.98
Acromegaly. BMJ (2010) 0.97